Non-classical structures among current platinum complexes with potential as antitumor drugs

Current Topics in Medicinal Chemistry

Volumn 11, Issue 21, 2011, Pages 2613-2622

  Quiroga, Adoracion G ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Biomolecules binding; Metallodrugs; Platinum

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; OXALIPLATIN; PICOPLATIN; THIOSEMICARBAZIDE DERIVATIVE; TRIPLATIN TETRANITRATE;

ARTICLE; BINDING KINETICS; BIOACCUMULATION; CATALYSIS; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; COMPETITIVE INHIBITION; CYCLIZATION; DNA MODIFICATION; DNA REPAIR; DRUG DESIGN; DRUG STRUCTURE; HETERONUCLEAR SINGLE QUANTUM COHERENCE; HUMAN; HYDROLYSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; NUCLEAR OVERHAUSER EFFECT; OXIDATION; SOLUBILITY; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

ANTINEOPLASTIC AGENTS; BLOOD PROTEINS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; DNA; DRUG DESIGN; HUMANS; NEOPLASMS; ORGANOPLATINUM COMPOUNDS; PLATINUM; PROTEIN BINDING; THIOSEMICARBAZONES;

EID: 80055076602     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802611798040723     Document Type: Article

References (102)

1. Front Matter. In: Cisplatin, Prof. Bernhard, L., Ed. 2006; pp I-XII.
2. Lombardino, J. G.; Lowe, J. A. The role of the medicinal chemist in drug discovery -Then and now. Nat. Rev. Drug. Discov., 2004, 3(10), 853-862.
3. Stoughton, R. B.; Friend, S. H. How molecular profiling could revolutionize drug discovery. Nat. Rev. Drug Discov., 2005, 4(4), 345-350.
4. Skladanowski, A.; Bozko, P.; Sabisz, M. DNA structure and integrity checkpoints during the cell cycle and their role in drug targeting and sensitivity of tumor cells to anticancer treatment. Chem. Rev., 2009, 109(7), 2951-2973.
5. Zhou, B.-B. S.; Zhang, H.; Damelin, M.; Geles, K. G.; Grindley, J. C.; Dirks, P. B. Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat. Rev. Drug Discov., 2009, 8 (10), 806-823.
6. Shewach, D. S.; Kuchta, R. D. Introduction to Cancer Chemotherapeutics. Chem. Rev., 2009, 109(7), 2859-2861.
7. Kelland, L. The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer, 2007, 7, (8), 573-584.
8. Lippert, B., Trans-diammineplatinum(II): What makes it different from cis-DDP? Coordination chemistry of a neglected relative of cisplatin and its interaction with nucleic acids. Metal. Ions. Biol. Sys., 1996, 33, 105-141.
9. Farrell, N.; Ha, T. T. B.; Souchard, J. P.; Wimmer, F. L.; Cros, S.; Johnson, N. P. cytostatic trans-platinum(Ii) complexes. J. Med. Chem., 1989, 32(10), 2240-2241.
10. Coluccia, M.; Nassi, A.; Loseto, F.; Boccarelli, A.; Mariggio, M. A.; Giordano, D.; Intini, F. P.; Caputo, P.; Natile, G. A transplatinum complex showing higher antitumor-activity than the cis congeners. J. Med. Chem., 1993, 36(4), 510-512.
11. Montero, E. I.; Diaz, S.; Gonzalez-Vadillo, A. M.; Perez, J. M.; Alonso, C.; Navarro-Ranninger, C. Preparation and characterization of novel trans-[PtCl2(amine)(isopropylamine)] compounds: Cytotoxic activity and apoptosis induction in ras-transformed cells. J. Med. Chem., 1999, 42(20), 4264-4268.
12. Kalinowska-Lis, U.; Ochocki, J.; Matlawska-Wasowska, K. Trans geometry in platinum antitumor complexes. Coord. Chem. Rev., 2008, 252, (12-14), 1328-1345.
13. Sheena, M. A.; Nicholas, P. F. Towards Antitumor Active trans-Platinum Compounds. Euro. J. Inorg. Chem., 2009, 2009, (10), 1293-1302.
14. Fojo, T.; Farrell, N.; Ortuzar, W.; Tanimura, H.; Weinstein, J.; Myers, T. G. Identification of non-cross-resistant platinum compounds with novel cytotoxicity profiles using the NCI anticancer drug screen and clustered image map visualizations. Crit. Rev. Oncol. Hematol., 2005, 53, (1), 25-34.
15. Najajreh, Y.; Perez, J. M.; Navarro-Ranninger, C.; Gibson, D. Novel soluble cationic trans-diaminedichloroplatinum(II) complexes that are active against cisplatin resistant ovarian cancer cell lines. J. Med. Chem., 2002, 45(24), 5189-5195.
16. Ramos-Lima, F. J.; Quiroga, A. G.; Perez, J. M.; Font-Bardia, M.; Solans, X.; Navarro-Ranninger, C. Synthesis and characterization of new transplatinum complexes containing phosphane groups -Cytotoxic studies in cisplatin-resistant cells. Eur. J. Inorg. Chem., 2003, (8), 1591-1598.
17. Ramos-Lima, F. J.; Quiroga, A. G.; Garcia-Serrelde, B.; Blanco, F.; Carnero, A.; Navarro-Ranninger, C. New trans-platinum drugs with phosphines and amines as carrier ligands induce apoptosis in tumor cells resistant to cisplatin. J. Med. Chem., 2007, 50(9), 2194-2199.
18. Ma, E. S. F.; Bates, W. D.; Edmunds, A.; Kelland, L. R.; Fojo, T.; Farrell, N. Enhancement of aqueous solubility and stability employing a trans acetate axis in trans planar amine platinum compounds while maintaining the biological profile. J. Med. Chem., 2005, 48(18), 5651-5654.
19. Quiroga, A. G.; Perez, J. M.; Alonso, C.; Navarro-Ranninger, C.; Farrell, N. Novel transplatinum(II) complexes with [N2O2] donor sets. Cellular pharmacology and apoptosis induction in Pam 212-ras cells. J. Med. Chem., 2006, 49(1), 224-231.
20. Radulovic, S.; Tesic, Z.; Manic, S. Trans-platinum complexes as anticancer drugs: Recent developments and future prospects. Curr. Med. Chem., 2002, 9(17), 1611-1618.
21. Coluccia, M.; Natile, G. Trans-platinum complexes in cancer therapy. Anticancer Agents Med. Chem., 2007, 7(1), 111-123.
22. Natile, G.; Coluccia, M. Antitumor active trans-platinum compounds. Met. Ions. Biol. Syst., 2004, 42, 209-250.
23. Timerbaev, A. R.; Hartinger, C. G.; Aleksenko, S. S.; Keppler, B. K. Interactions of antitumor metallodrugs with serum proteins: advances in characterization using modern analytical methodology. Chem. Rev., 2006, 106(6), 2224-2248.
24. Barton, S. J.; Barnham, K. J.; Habtemariam, A.; Sue, R. E.; Sadler, P. J. PKa values of aqua ligands of platinum(II) anticancer complexes: H-1, N-15 and Pt-195 NMR studies of cis-and trans-PtCl2(NH3)(cyclohexylamine). Inorg. Chim. Acta, 1998, 273, (1-2), 8-13.
25. Liu, Y. Z.; Intini, F. P.; Natile, G.; Sletten, E. Kinetic study of the reaction between an antitumor N-15 labeled trans-platinum iminoether complex and GMP by H-1, N-15 HMQC NMR. J. Chem. Soc. Dalton, 2002, (18), 3489-3495.
26. McGowan, G.; Parsons, S.; Sadler, P. J. Contrasting chemistry of cis-and trans-platinum(II) diamine anticancer compounds: hydrolysis studies of picoline complexes. Inorg. Chem., 2005, 44(21), 7459-67.
27. Cubo, L.; Quiroga, A. G.; Zhang, J.; Thomas, D. S.; Carnero, A.; Navarro-Ranninger, C.; Berners-Price, S. J. Influence of amine ligands on the aquation and cytotoxicity of trans-diamine platinum(ii) anticancer complexes. Dalton Trans., 2009, (18), 3457-3466.
28. Kelland, L. R.; Barnard, F. J.; Evans, I. G.; Murrer, B. A.; Theobald, B. R. C.; Wyer, S. B.; Goddard, P. M.; Jones, M.; Valenti, M. Synthesis and in vitro and in vivo antitumor activity of a series of trans platinum antitumor complexes. J. Med. Chem., 1995, 38(16), 3016-3024.
29. Cubo, L.; Thomas, D. S.; Zhang, J.; Quiroga, A. G.; Navarro-Ranninger, C.; Berners-Price, S. J. [1H,15N] NMR studies of the aquation of cis-diamine platinum(II) complexes. Inorg. Chim. Acta, 2009, 362, 1022-1026.
30. Davies, M. S.; Berners-Price, S. J.; Hambley, T. W. Slowing of cisplatin aquation in the presence of DNA but not in the presence of phosphate: Improved understanding of sequence selectivity and the roles of monoaquated and diaquated species in the binding of cisplatin to DNA. Inorg. Chem., 2000, 39 (25), 5603-5613.
31. Campbell, M. A.; Miller, P. S. Phosphodiester-Mediated Reaction of Cisplatin with Guanine in Oligodeoxyribonucleotides. Biochemistry, 2008, 47(48), 12931-12938.
32. Centerwall, C. R.; Goodisman, J.; Kerwood, D. J.; Dabrowiak, J. C. Cisplatin carbonato complexes. implications for uptake, antitumor properties, and toxicity. J. Am. Chem. Soc., 2005, 127(37), 12768-12769.
33. Todd, R. C.; Lovejoy, K. S.; Lippard, S. J. Understanding the effect of carbonate ion on cisplatin binding to DNA. J. Am. Chem. Soc., 2007, 129, (20), 6370-1.
34. Casini, A.; Gabbiani, C.; Mastrobuoni, G.; Pellicani, R. Z.; Intini, F. P.; Arnesano, F.; Natile, G.; Moneti, G.; Francese, S.; Messori, L. Insights into the molecular mechanisms of protein platination from a case study: The reaction of anticancer Platinum(II) iminoethers with horse heart cytochrome c. Biochemistry, 2007, 46(43), 12220-12230.
35. Cubo, L.; Casini, A.; Gabbiani, C.; Mastrobuoni, G.; Messori, L.; Jimenez-Barbero, J.; Navarro-Ranninger, C.; Quiroga, A. G. Solution behaviour and biomolecular interactions of two cytotoxic trans-platinum(ii) complexes bearing aliphatic amine ligands. Chem-Eur. J., 2009, 15(36), 9139-9146.
36. Zhang, J. Y.; Thomas, D. S.; Berners-Price, S. J.; Farrell, N. Effects of geometric isomerism and anions on the kinetics and mechanism of the stepwise formation of long-range DNA interstrand crosslinks by dinuclear platinum antitumor complexes. Chem-Eur. J., 2008, 14(21), 6391-6405.
37. Li, C.; Li, Z. Y.; Sletten, E.; Arnesano, F.; Losacco, M.; Natile, G.; Liu, Y. Z. Methionine can favor DNA platination by trans-coordinated platinum antitumor drugs. Angew. Chem. Int. Edit., 2009, 48(45), 8497-8500.
38. Jung, Y.; Lippard, S. J. Direct cellular responses to platinum-induced DNA damage. Chem. Rev., 2007, 107, (5), 1387-1407.
39. Todd, R. C.; Lippard, S. J. Inhibition of transcription by platinum antitumor compounds. Metallomics, 2009, 1, (4), 280-291.
40. Klein, A. V.; Hambley, T. W. Platinum Drug Distribution in Cancer Cells and Tumors. Chem. Rev., 2009, 109, (10), 4911-4920.
41. Ohndorf, U.-M.; Rould, M. A.; He, Q.; Pabo, C. O.; Lippard, S. J. Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins. Nature, 1999, 399, (6737), 708-712.
42. van Boom, S. S. G. E.; Chen, B. W.; Teuben, J. M.; Reedijk, J. Platinum thioether bonds can be reverted by guanine N7 bonds in Pt(dien)2+ model adducts. Inorg. Chem., 1999, 38, (7), 1450-1455.
43. Yu, C.; Zijian, G.; Peter, J. S. In: 195Pt-and 15N-NMR Spectroscopic Studies of Cisplatin Reactions with Biomolecules. Cisplatin, Prof. Bernhard, L., Ed. 2006; pp 293-318.
44. Reedijk, J.; Teuben, J. M. In: Platinum-Sulfur Interactions Involved in Antitumor Drugs, Rescue Agents, and Biomolecules. Cisplatin, Prof. Bernhard, L., Ed. 2006; pp 339-362.
45. Bierbach, U.; Farrell, N. Structural and reactivity studies on the ternary system guanine/methionine/ trans -[PtCl2(NH3)L] (L=NH3, quinoline): implications for the mechanism of action of nonclassical trans -platinum antitumor complexes. J. Biol. Inorg. Chem., 1998, 3, (6), 570-580.
46. Anzellotti, A.; Stefan, S.; Gibson, D.; Farrell, N. Donor atom preferences in substitution reactions of trans-platinum mononucleobase compounds: Implications for DNA-protein selectivity. Inorg. Chim. Acta, 2006, 359, (9), 3014-3019.
47. Quintal, S. M. O.; Qu, Y.; Quiroga, A. G.; Moniodis, J.; Nogueira, H. I. S.; Farrell, N, Pyridine-carboxylate complexes of platinum. Effect of N,O-chelate formation on model bifunctional DNA-DNA and DNA-protein interactions. Inorg. Chem., 2005, 44, (15), 5247-5253.
48. Anzellotti, A. I.; Liu, Q.; Bloemink, M. J.; Scarsdale, J. N.; Farrell, N. Targeting retroviral Zn finger-DNA interactions: A small-molecule approach using the electrophilic nature of trans-platinum-nucleobase compounds. Chem. Biol., 2006, 13, (5), 539-548.
49. Liu, Q.; Golden, M.; Darensbourg, M. Y.; Farrell, N. Thiolate-bridged heterodinuclear platinum-zinc chelates as models for ternary platinum-DNA-protein complexes and zinc ejection from zinc fingers. Evidence from studies using ESI-mass spectrometry. Chem. Commun., 2005, (34), 4360-4362.
50. Almaraz, E.; de Paula, Q. A.; Liu, Q.; Reibenspies, J. H.; Darensbourg, M. Y.; Farrell, N. P. Thiolate bridging and metal exchange in adducts of a zinc finger model and Pt-II complexes: Biomimetic studies of protein/Pt/DNA interactions. J. Am. Chem. Soc., 2008, 130(19), 6272-6280.
51. Knipp, M.; Karotki, A. V.; Chesnov, S.; Natile, G.; Sadler, P. J.; Brabec, V.; Vasak, M. Reaction of Zn(7)Metallothionein with cis-and trans-[Pt(N-donor)(2)Cl-2] anticancer complexes: trans-Pt-II complexes retain their N-donor ligands. J. Med. Chem., 2007, 50, (17), 4075-4086.
52. Karotki, A. V.; Vasak, M. Interaction of metallothionein-2 with platinum-modified 5 '-guanosine monophosphate and DNA. Biochemistry, 2008, 47(41), 10961-10969.
53. Rao, L.; Bierbach, U. Kinetically favored platination of adenine in the g-rich human telomeric repeat. J. Am. Chem. Soc., 2007, 129, (51), 15764-15765.
54. Reed, J. E.; Neidle, S.; Vilar, R. Stabilisation of human telomeric quadruplex DNA and inhibition of telomerase by a platinum-phenanthroline complex. Chem. Commun., 2007, (42), 4366-4368.
55. Farrell, N.; Povirk, L. F.; Dange, Y.; DeMasters, G.; Gupta, M. S.; Kohlhagen, G.; Khan, Q. A.; Pommier, Y.; Gewirtz, D. A. Cytotoxicity, DNA strand breakage and DNA-protein crosslinking by a novel transplatinum compound in human A2780 ovarian and MCF-7 breast carcinoma cells. Biochem. Pharm., 2004, 68(5), 857-866.
56. Hartinger, C. G.; Tsybin, Y. O.; Fuchser, J.; Dyson, P. J. Characterization of platinum anticancer drug protein-binding sites using a top-down mass spectrometric approach. Inorg. Chem., 2008, 47(1), 17-19.
57. Casini, A.; Gabbiani, C.; Michelucci, E.; Pieraccini, G.; Moneti, G.; Dyson, P. J.; Messori, L. Exploring metallodrug-protein interactions by mass spectrometry: comparisons between platinum coordination complexes and an organometallic ruthenium compound. J. Biol. Inorg. Chem., 2009, 14, (5), 761-770.
58. Gabbiani, C.; Casini, A.; Mastrobuoni, G.; Kirshenbaum, N.; Moshel, O.; Pieraccini, G.; Moneti, G.; Messori, L.; Gibson, D. Peculiar mechanistic and structural features of the carboplatincytochrome c system revealed by ESI-MS analysis. J. Biol. Inorg. Chem., 2008, 13(5), 755-764.
59. Berners-Price, S. J.; Ronconi, L.; Sadler, P. J. Insights into the mechanism of action of platinum anticancer drugs from multinuclear NMR spectroscopy. Prog. Nucl. Mag. Res. Sp., 2006, 49(1), 65-98.
60. Siddik, Z. H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene, 2003, 22(47), 7265-7279.
61. Mueller, S.; Schittenhelm, M.; Honecker, F.; Malenke, E.; Lauber, K.; Wesselborg, S.; Hartmann, J. T.; Bokemeyer, C.; Mayer, F. Cell-cycle progression and response of germ cell tumors to cisplatin in vitro. Int. J. Oncol., 2006, 29(2), 471-479.
62. Ormerod, M. G.; Orr, R. M.; Peacock, J. H. The role of apoptosis in cell-killing by cisplatin -a flow cytometric study. Brit. J. Cancer, 1994, 69(1), 93-100.
63. Sorenson, C. M.; Eastman, A. Influence of cis-diamminedichloroplatinum(Ii) on DNA-synthesis and cell-cycle progression in excision repair proficient and deficient chinese-hamster ovary cells. Cancer Res., 1988, 48(23), 6703-6707.
64. Sorenson, C. M.; Eastman, A. Mechanism of cis-diamminedichloroplatinum(Ii)-induced cyto-toxicity -role of G2 arrest and DNA double-strand breaks. Cancer Res., 1988, 48(16), 4484-4488.
65. Coluccia, M.; Nassi, A.; Boccarelli, A.; Giordano, D.; Cardellicchio, N.; Intini, F. P.; Natile, G.; Barletta, A.; Paradiso, A., In vitro antitumour activity and cellular pharmacological properties of the platinum-iminoether complex trans-[PtCl2{E-HN=C(OMe)Me}(2)]. Int. J. Oncol., 1999, 15(5), 1039-1044.
66. Boccarelli, A.; Giordano, D.; Natile, G.; Coluccia, M. Differential processing of antitumour-active and antitumour-inactive trans platinum compounds by SKOV-3 ovarian cancer cells. Biochem. Pharmacol., 2006, 72(3), 280-292.
67. Zhang, C. X.; Lippard, S. J. New metal complexes as potential therapeutics. Curr. Opin. Chem. Biol., 2003, 7(4), 481-489.
68. Ramos-Lima, F. J.; Quiroga, A. G.; Perez, J. M.; Navarro-Ranninger, C. Preparation, characterization and cytotoxic activity of new compounds trans-[PtCl2NH3(3-(hydroxymethyl)-pyridine)] and trans-[PtCl2NH3(4-(hydroxymethyl)-pyridine)]. Polyhedron, 2003, 22(25-26), 3379-3381.
69. Stehlikova, K.; Kasparkova, J.; Novakova, O.; Martinez, A.; Moreno, V.; Brabec, V. Recognition of DNA modified by trans-[PtCl2NH3(4-hydroxymethylpyridine)] by tumor suppressor protein p53 and character of DNA adducts of this cytotoxic complex. Febs J., 2006, 273(2), 301-314.
70. Ramos-Lima, F. J.; Moneo, V.; Quiroga, A. G.; Carnero, A.; Navarro-Ranninger, C. The role of p53 in the cellular toxicity by active trans-platinum complexes containing isopropylamine and hydroxymethylpyridine. Eur. J. Med. Chem., 2010, 45(1), 134-141.
71. Kabolizadeh, P.; Ryan, J.; Farrell, N. Differences in the cellular response and signaling pathways of cisplatin and BBR3464 ([trans-PtCl(NH3)(2)]2μ-(trans-Pt(NH3)(2)(H2N(CH2)(6)-NH2)2)]4+) influenced by copper homeostasis. Biochem. Pharmacol., 2007, 73(9), 1270-1279.
72. Servidei, T.; Ferlini, C.; Riccardi, A.; Meco, D.; Scambia, G.; Segni, G.; Manzotti, C.; Riccardi, R. The novel trinuclear platinum complex BBR3464 induces a cellular response different from cisplatin. Eur. J. Cancer (Oxford, England: 1990), 2001, 37(7), 930-938.
73. Farina, V. High-turnover palladium catalysts in cross-coupling and heck chemistry: a critical overview. Adv. Synthesis Catalysis, 2004, 346(13-15), 1553-1582.
74. Dupont, J.; Consorti, C. S.; Spencer, J. The potential of palladacycles: More than just precatalysts. Chem. Rev., 2005, 105(6), 2527-2571.
75. Navarro-Ranniger, C.; Lopez-Solera, I.; Perez, J. M.; Rodriguez, J.; Garcia-Ruano, J. L.; Raithby, P. R.; Masaguer, J.; Alonso, C. Analysis of two cycloplatinated compounds derived from N-(4-methoxyphenyl)-.alpha.-benzoylbenzylidenamine. Comparison of the activity of these compounds with other isostructural cyclopal-ladated compounds. J. Med. Chem., 1993, 36(24), 3795-3801.
76. Quiroga, A. G.; Perez, J. M.; Lopez-Solera, I.; Masaguer, J. R.; Luque, A.; Roman, P.; Edwards, A.; Alonso, C.; Navarro-Ranninger, C. Novel tetranuclear orthometalated complexes of Pd(II) and Pt(II) derived from p-isopropylbenzaldehyde thiosemi-carbazone with cytotoxic activity in cis-DDP resistant tumor cell lines. Interaction of these complexes with DNA. J. Med. Chem., 1998, 41(9), 1399-1408.
77. Quiroga, A. G.; Ranninger, C. N. Contribution to the SAR field of metallated and coordination complexes. Studies of the palladium and platinum derivatives with selected thiosemicarbazones as antitumoral drugs. Coord. Chem. Rev., 2004, 248, (1-2), 119-133.
78. Spencer, J.; Casini, A.; Zava, O.; Rathnam, R. P.; Velhanda, S. K.; Pfeffer, M.; Callear, S. K.; Hursthouse, M. B.; Dyson, P. J. Excellent correlation between cathepsin B inhibition and cytotoxicity for a series of palladacycles. Dalton T, 2009, (48), 10731-10735.
79. Duffy, K. J.; Price, A. T.; Delorme, E.; Dillon, S. B.; Duquenne, C.; Erickson-Miller, C.; Giampa, L.; Huang, Y.; Keenan, R. M.; Lamb, P.; Liu, N.; Miller, S. G.; Rosen, J.; Shaw, A. N.; Smith, H.; Wiggall, K. J.; Zhang, L.; Luengo, J. I. Identification of a pharmacophore for thrombopoietic activity of Small, non-peptidyl molecules. 2. Rational design of naphtha [1,2-d]imidazole thrombopoietin mimics. J. Med. Chem., 2002, 45(17), 3576-3578.
80. Maurer, R. I.; Blower, P. J.; Dilworth, J. R.; Reynolds, C. A.; Zheng, Y.; Mullen, G. E. D. Studies on the Mechanism of Hypoxic Selectivity in Copper Bis(Thiosemicarbazone) Radiopharmaceuticals. J. Med. Chem., 2002, 45(7), 1420-1431.
81. Ren, S.; Wang, R.; Komatsu, K.; Bonaz-Krause, P.; Zyrianov, Y.; McKenna, C. E.; Csipke, C.; Tokes, Z. A.; Lien, E. J. Synthesis, Biological evaluation, and quantitative structureâˆ'activity relationship analysis of new schiff bases of hydroxysemicarbazide as potential antitumor agentsâ. J. Med. Chem., 2001, 45(2), 410-419.
82. Pirrung, M. C.; Pansare, S. V.; Sarma, K. D.; Keith, K. A.; Kern, E. R. Combinatorial optimization of isatin-thiosemicarbazones as anti-poxvirus agents. J. Med. Chem., 2005, 48(8), 3045-3050.
83. Du, X.; Guo, C.; Hansell, E.; Doyle, P. S.; Caffrey, C. R.; Holler, T. P.; McKerrow, J. H.; Cohen, F. E. Synthesis and structureâˆ'activity relationship study of potent trypanocidal thio semi-carbazone inhibitors of the trypanosomal cysteine protease cruzain. J. Med. Chem., 2002, 45(13), 2695-2707.
84. Greenbaum, D. C.; Mackey, Z.; Hansell, E.; Doyle, P.; Gut, J.; Caffrey, C. R.; Lehrman, J.; Rosenthal, P. J.; McKerrow, J. H.; Chibale, K. Synthesis and structureâˆ'activity relationships of para-siticidal thiosemicarbazone cysteine protease inhibitors against plasmodium falciparum, trypanosoma brucei, and trypanosoma cruzi. J. Med. Chem., 2004, 47(12), 3212-3219.
85. Hall, M. D.; Salam, N. K.; Hellawell, J. L.; Fales, H. M.; Kensler, C. B.; Ludwig, J. A.; SzakaÌcs, G.; Hibbs, D. E.; Gottesman, M. M. Synthesis, activity, and pharmacophore development for isatin-thiosemicarbazones with selective activity toward multidrug-resistant cells. J. Med. Chem., 2009, 52(10), 3191-3204.
86. Bermejo, M. R.; González-Noya, A. M.; Pedrido, R. M.; Romero, M. J.; Vázquez, M. Route to cluster helicates13. Angew Chem. Int. Edit., 2005, 44(27), 4182-4187.
87. Casas, J. S.; García-Tasende, M. S.; Sordo, J. Main group metal complexes of semicarbazones and thiosemicarbazones. A structural review. Coord. Chem. Rev., 2000, 209(1), 197-261.
88. Lobana, T. S.; Sharma, R.; Bawa, G.; Khanna, S. Bonding and structure trends of thiosemicarbazone derivatives of metals--An overview. Coord. Chem. Rev., 2009, 253(7-8), 977-1055.
89. Kovala-Demertzi, D.; Papageorgiou, A.; Papathanasis, L.; Alexandratos, A.; Dalezis, P.; Miller, J. R.; Demertzis, M. A. In vitro and in vivo antitumor activity of platinum(II) complexes with thiosemi-carbazones derived from 2-formyl and 2-acetyl pyridine and containing ring incorporated at N(4)-position: Synthesis, spectroscopic study and crystal structure of platinum(II) complexes with thiosemicarbazones, potential anticancer agents. Eur. J. Med. Chem., 2009, 44(3), 1296-1302.
90. Kovala-Demertzi, D.; Boccarelli, A.; Demertzis, M. A.; Coluccia, M. In vitro antitumor activity of 2-acetyl pyridine 4N-ethyl thiosemicarbazone and its platinum(II) and palladium(II) com-plexes. Chemotherapy, 2007, 53(2), 148-152.
91. Kowol, C. R.; Berger, R.; Eichinger, R.; Roller, A.; Jakupec, M. A.; Schmidt, P. P.; Arion, V. B.; Keppler, B. K. Gallium(III) and iron(III) complexes of α-N-heterocyclic thiosemicarbazones:⠉ synthesis, characterization, cytotoxicity, and interaction with ribo-nucleotide reductase. J. Med. Chem., 2007, 50(6), 1254-1265.
92. Kowol, C. R.; Trondl, R.; Heffeter, P.; Arion, V. B.; Jakupec, M. A.; Roller, A.; Galanski, M.; Berger, W.; Keppler, B. K. Impact of metal coordination on cytotoxicity of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (triapine) and novel insights into terminal dimethylation. J. Med. Chem., 2009, 52(16), 5032-5043.
93. Yu, Y.; Kalinowski, D. S.; Kovacevic, Z.; Siafakas, A. R.; Jansson, P. J.; Stefani, C.; Lovejoy, D. B.; Sharpe, P. C.; Bernhardt, P. V.; Richardson, D. R. Thiosemicarbazones from the old to new: Iron chelators that are more than just ribonucleotide reductase inhibitors. J. Med. Chem., 2009, 52(17), 5271-5294.
94. Quiroga, A. G.; Perez, J. M.; Lopez-Solera, I.; Montero, E. I.; Masaguer, J. R.; Alonso, C.; Navarro-Ranninger, C. Binuclear chlorobridged palladated and platinated complexes derived from p-isopropylbenzaldehyde thiosemicarbazone with cytotoxicity against cisplatin resistant tumor cell lines. J. Inorg. Biochem., 1998, 69(4), 275-281.
95. Quiroga, A. G.; Perez, J. M.; Montero, E. I.; Masaguer, J. R.; Alonso, C.; Navarro-Ranninger, C. Palladated and platinated com-plexes derived from phenylacetaldehyde thiosemicarbazone with cytotoxic activity in cis-DDP resistant tumor cells. Formation of DNA interstrand cross-links by these complexes. J. Inorg. Biochem., 1998, 70(2), 117-123.
96. Quiroga, G. A.; Cubo, L.; Sanz Miguel, P. J.; Moneo, V.; Carnero, A.; Navarro-ranninger, c. isolation of an intermediate in the platination of p-nitroacetophenone 4-methylthiosemicarbazone: potential application as an antitumor drug. Eur. J. Inorg. Chem., 2008, 2008, (8), 1183-1187.
97. Aleman, J.; del Solar, V.; Navarro-Ranninger, C. Anticancer platinum complexes as non-innocent compounds for catalysis in aqueous media. Chem. Commun., 2010, 46(3), 454-456.
98. Furstner, A.; Davies, P. W., Catalytic carbophilic activation: Catalysis by platinum and gold pi acids. Angew. Chem. Int. Edit., 2007, 46(19), 3410-3449.
99. Yanagihara, N.; Lambert, C.; Iritani, K.; Utimoto, K.; Nozaki, H. Palladium-catalyzed regioselective and stereoselective cyclized coupling of lithium alkynoates with allyl halides. J. Am. Chem. Soc., 1986, 108(10), 2753-2754.
100. Genin, E.; Toullec, P. Y.; Antoniotti, S.; Brancour, C.; Genet, J. P.; Michelet, W. Room temperature Au(I)-catalyzed exo-selective cycloisomerization of acetylenic acids: An entry to functionalized gamma-lactones. J. Am. Chem. Soc., 2006, 128(10), 3112-3113.
101. Pizarro, A. M.; Munk, V. P.; Navarro-Ranninger, C.; Sadler, P. J. Hydrolysis triggers oxidation of a trans diamine platinum(II) anti-cancer complex. Angew, Chem, Int, Edit, 2003, 42(43), 5339-5342.
102. Macazaga, M. J.; Rodriguez, J.; Quiroga, A. G.; Peregina, S.; Carnero, A.; Navarro-Ranninger, C.; Medina, R. M. Platinum(iv) complexes of 3-and 4-picolinic acids containing ammine or isopropylamine ligands -synthesis, characterization, x-ray structures, and evaluation of their cytotoxic activity against cancer cell lines. Eur. J. Inorg. Chem., 2008, (30), 4762-4769.